CyPass Micro-Stent

Intraocular Pressure Lowering Implant

FDA Premarket Approval P150037

This medical device has supplements. The device description/function or indication may have changed. Be sure to look at the supplements to get an up-to-date information on device changes. The labeling included below is the version at time of approval of the original pma or panel track supplement and may not represent the most recent labeling.

Pre-market Approval Supplement Details

Approval for the cypass® system, model 241-s. This device is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (iop) in adult patients with mild to moderate primary open-angle glaucoma (poag).

DeviceCyPass Micro-Stent
Classification NameIntraocular Pressure Lowering Implant
Generic NameIntraocular Pressure Lowering Implant
ApplicantAlcon Research, Ltd
Date Received2015-10-21
Decision Date2016-07-29
Notice Date2016-08-18
PMAP150037
SupplementS
Product CodeOGO
Docket Number16M-2333
Advisory CommitteeOphthalmic
Expedited ReviewNo
Combination Product No
Applicant Address Alcon Research, Ltd 6201 South Freeway fort Worth, TX 76134
Summary:Summary of Safety and Effectiveness
Labeling: Labeling Labeling Part 2
Post-Approval Study:Show Report Schedule and Study Progress
Approval Order: Approval Order

Supplemental Filings

Supplement NumberDateSupplement Type
P150037Original Filing
S014 2019-12-20 Normal 180 Day Track No User Fee
S013
S012
S011 2018-07-16 30-day Notice
S010 2018-06-25 30-day Notice
S009 2018-05-04 30-day Notice
S008 2017-09-25 Normal 180 Day Track
S007 2017-07-27 Normal 180 Day Track No User Fee
S006 2017-06-02 Normal 180 Day Track No User Fee
S005 2017-04-20 30-day Notice
S004 2017-03-15 30-day Notice
S003 2016-11-03 30-day Notice
S002 2016-08-26 Normal 180 Day Track No User Fee
S001 2016-08-24 Normal 180 Day Track No User Fee

NIH GUDID Devices

Device IDPMASupp
00380657540075 P150037 008

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.